Enveric Biosciences, Inc. Common Stock
ENVBStock
$1.36−91.06%52W
Market Cap$4.86M
P/E—
Div yield—
Beta1.17
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-77.65%
Price vs S&P 500 (4W)-4.25%
VGM Score37.61
Market Capitalization$4.86M
Analyst Recommendations
Nov 2025
Dec 2025
Jan 2026
Feb 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ENVBEnveric Biosciences, Inc. Common Stock | B | D | F | $1.36 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Enveric Biosciences develops novel small-molecule therapeutics targeting depression, anxiety, addiction, and other psychiatric disorders through neuroplastogenicity. Its lead program, EB-003, is a first-in-class candidate designed to promote neuroplasticity without inducing hallucinations. The company is also advancing EB-002, a synthetic psilocin prodrug, as a next-generation treatment for psychiatric disorders.